Gastroenterology
Latest news
416 articles · 20 / page
Prehabilitation in Sarcopenic Patients Undergoing Major Hepatectomy: Evidence from the PREHEP Trial
A 6-week multimodal prehabilitation program combining exercise and nutrition significantly reduces postoperative morbidity in sarcopenic patients undergoing major liver resection, highlighting a promising strategy to improve surgical outcom
Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score
Metabolic dysfunction and MASLD elevate hepatocellular carcinoma risk in chronic hepatitis B patients. The PAGE-B score effectively stratifies this risk, especially in non-cirrhotic patients, while cirrhotic patients still require careful m
Simplifying Ulcerative Colitis Treatment: Evaluating a Single 1600 mg 5-ASA Tablet Regimen in the EASI Trial
The EASI trial compared a once-daily 1600 mg 5-ASA tablet with the conventional three 800 mg tablet regimen for ulcerative colitis, finding similar adherence and relapse rates, suggesting a feasible simpler alternative.
IL23R Polymorphism as a Genetic Predictor of Paradoxical Psoriasis in Anti-TNFα-Treated IBD Patients
The IL23R1142G>A genetic variant strongly predicts paradoxical psoriasis in inflammatory bowel disease patients undergoing anti-TNFα therapy, guiding personalized treatment decisions.
Persistent High Mortality in Severe Alcohol-Associated Hepatitis: Insights from a Five-Decade Meta-Analysis
This meta-analysis reveals that short-term mortality in severe alcohol-associated hepatitis remains high, with no significant improvement over the past four decades despite advances in care, underscoring the urgent need for better therapies
Obeticholic Acid Non-Response Signals Higher Clinical Risk in Primary Biliary Cholangitis
In primary biliary cholangitis (PBC) patients treated with obeticholic acid (OCA), biochemical non-response strongly predicts a higher risk of clinical events including liver decompensation and mortality, underscoring the need for improved
Gut Microbiota Dysbiosis in Cirrhotic Portal Hypertension: Unraveling Microbial Contributions to Disease Progression
Altered gut microbiota composition and metabolism exacerbate cirrhotic portal hypertension, highlighting potential microbiome-targeted therapies to mitigate disease progression.
Optimizing Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection: Empirical Donor Selection and Two-Dose Regimen Enhance Cure Rates
This study demonstrates that empirical donor exclusion combined with a two-dose capsule regimen significantly improves cure rates in Clostridioides difficile infection treated with encapsulated faecal microbiota transplantation (FMT).
Opioid Use in Rome IV Irritable Bowel Syndrome: Prevalence and Impact on Quality of Life and Healthcare in the UK
One in five UK patients with Rome IV IBS regularly use opioids, associated with worse quality of life, more psychological distress, and increased healthcare costs, highlighting a critical need for opioid stewardship in IBS management.
Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis
A phase 2b trial demonstrates that several noninvasive tests reliably reflect treatment response to semaglutide in patients with metabolic dysfunction-associated steatohepatitis, correlating with histologic improvements over 72 weeks.
Gut Microbiota as a Key Determinant of Quality of Life Impairment in Inflammatory Bowel Disease
A recent cross-sectional study reveals that alterations in gut microbiota correlate more strongly with impaired health-related quality of life in IBD patients than clinical disease activity, suggesting novel microbial therapeutic targets be
FDA Approves Golimumab (Simponi) for Pediatric Ulcerative Colitis: A New Therapeutic Option
The FDA has approved golimumab (Simponi) for treating moderately to severely active ulcerative colitis in children weighing at least 15 kg, based on the PURSUIT 2 phase 3 study demonstrating significant clinical remission and safety.
Menopausal Hormone Therapy and Reduced Risk of Upper Gastrointestinal Cancers: Insights From a Large Nordic Population Study
A large Nordic study finds menopausal hormone therapy reduces the risk of esophageal and gastric cancers by up to 30%, especially with combined estrogen-progestin systemic formulations.
Revisiting Rehydration Strategies in Severe Acute Malnutrition with Gastroenteritis: Intravenous Versus Oral Approaches
A recent trial assessing intravenous versus oral rehydration in children with severe acute malnutrition and gastroenteritis found no mortality difference at 96 hours, challenging fears of fluid overload and supporting cautious consideration
Primary Sclerosing Cholangitis in a 45-Year-Old Male: A Case Report
A 45-year-old male presents with cholestatic liver enzyme elevation and pruritus, diagnosed with primary sclerosing cholangitis confirmed by imaging and liver biopsy. Clinical management and prognosis are discussed.
Cendakimab: A Promising Therapeutic for Eosinophilic Esophagitis in Adolescents and Adults
Cendakimab, a monoclonal antibody targeting IL-13, shows significant improvements in symptoms, histologic response, and endoscopic features in eosinophilic esophagitis, with a tolerable safety profile through 48 weeks.
Decoding the Role of Reflux Secondary Bile Acids in Barrett’s Esophagus: Microbiome and Transcriptome Insights
This study reveals that elevated reflux secondary bile acids in Barrett’s esophagus influence the esophageal microbiome and gene expression, highlighting potential mechanisms underpinning progression to esophageal adenocarcinoma.
The Withdrawal of OCALIVA: Impact and Implications for Primary Biliary Cholangitis Treatment
Intercept Pharmaceuticals withdraws OCALIVA from the US market following FDA demands due to safety concerns and lack of proven efficacy in PBC, prompting suspension of related clinical trials and significant shifts in therapeutic landscape.
Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology
AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.
HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy
A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatm
Browse by specialty
Open language-specific specialty feeds and department pages.